abrdn Life Sciences Investors (NYSE:HQL) Increases Dividend to $0.56 Per Share

abrdn Life Sciences Investors (NYSE:HQL) announced a quarterly dividend on Tuesday, February 10th. Shareholders of record on Friday, February 20th will be given a dividend of 0.56 per share on Tuesday, March 31st. This represents a c) dividend on an annualized basis and a dividend yield of 13.3%. The ex-dividend date is Friday, February 20th. This is a 12.0% increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50.

abrdn Life Sciences Investors Stock Down 0.1%

Shares of NYSE:HQL traded down $0.02 during trading on Wednesday, hitting $16.90. 115,403 shares of the company were exchanged, compared to its average volume of 135,330. abrdn Life Sciences Investors has a 1-year low of $10.55 and a 1-year high of $17.80. The business’s 50 day moving average is $16.96 and its 200-day moving average is $15.87.

Institutional Trading of abrdn Life Sciences Investors

A number of hedge funds have recently made changes to their positions in HQL. WNY Asset Management LLC raised its holdings in abrdn Life Sciences Investors by 3.4% in the 2nd quarter. WNY Asset Management LLC now owns 24,955 shares of the company’s stock valued at $320,000 after buying an additional 821 shares during the last quarter. Kingsview Wealth Management LLC raised its stake in abrdn Life Sciences Investors by 2.8% during the second quarter. Kingsview Wealth Management LLC now owns 36,743 shares of the company’s stock worth $471,000 after buying an additional 1,000 shares during the last quarter. Flagship Harbor Advisors LLC lifted its holdings in abrdn Life Sciences Investors by 0.3% in the second quarter. Flagship Harbor Advisors LLC now owns 341,959 shares of the company’s stock valued at $4,380,000 after buying an additional 1,082 shares during the period. Samalin Investment Counsel LLC boosted its position in abrdn Life Sciences Investors by 6.7% during the second quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock valued at $279,000 after acquiring an additional 1,366 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its holdings in abrdn Life Sciences Investors by 0.9% during the 2nd quarter. Advisors Asset Management Inc. now owns 160,173 shares of the company’s stock worth $2,052,000 after acquiring an additional 1,487 shares during the period. 32.21% of the stock is owned by institutional investors and hedge funds.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.